Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...

Research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Intuitive Surgical (NASDAQ:ISRG – Free Report) had its target price boosted by JPMorgan Chase & Co. from $575.00 to $675.00 ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

Walgreens Boots Alliance Inc (WBA) stock saw a decline, ending the day at $11.37 which represents a decrease of $-1.15 or -9.19% from the prior close of $12.52. The stock opened at $11.72 and touched ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...